Kura Oncology Inc (NASDAQ:KURA)
| 12.59 Delayed Data As of May 20 |  +0.46 / +3.79%Today’s Change | 10.41 Today|||52-Week Range 24.59 | -10.07% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $839.9M |
Company Description
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Contact Information
Kura Oncology, Inc. 12730 High Bluff Drive San Diego California 92130 |
Employees
Shareholders
| Other institutional | 70.21% |
| Mutual fund holders | 28.06% |
| Individual stakeholders | 12.78% |
Top Executives
| Troy E. Wilson | Chairman, President, CEO & Chief Financial Officer |
| Kathleen Ford | Chief Operating Officer |
| Mollie Leoni | Senior Vice President-Clinical Development |
| Stephen Dale | Chief Medical Officer |
| Blake Tomkinson | Vice President-Clinical Development |
